Novartis Ag (NVSEF) Cash from Investing Activities (2009 - 2025)

Novartis Ag has disclosed Cash from Investing Activities across 15 years of filings, most recently posting -$2.1 billion for Q4 2025.

• Cash from Investing Activities for Q4 2025 came in at -$2.1 billion, up 48.76% year-over-year; the trailing twelve-month figure through Dec 2025 was -$4.9 billion (up 43.2% YoY), and the FY2025 annual result was -$4.9 billion, up 35.09% from the prior year.
• Cash from Investing Activities came in at -$2.1 billion for Q4 2025 at Novartis Ag, down from -$860.0 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $9.7 billion in Q4 2023 to a low of -$11.6 billion in Q2 2022.
• The 5-year median for Cash from Investing Activities is -$899.0 million (2024), against an average of -$1.1 billion.
• Across the five-year window, Cash from Investing Activities sank 11965.31% in 2022 and jumped 530.62% in 2023, its largest moves.
• Novartis Ag's Cash from Investing Activities stood at $883.0 million in 2021, then sank by 356.29% to -$2.3 billion in 2022, then surged by 530.62% to $9.7 billion in 2023, then tumbled by 142.13% to -$4.1 billion in 2024, then jumped by 48.76% to -$2.1 billion in 2025.
• The last three Cash from Investing Activities figures came in at -$2.1 billion (Q4 2025), -$860.0 million (Q3 2025), and -$2.2 billion (Q2 2025), per Business Quant data.